TP53 and large cell neuroendocrine carcinoma: Notably, TP53/RB1 co‐alteration occurs in ~36% of pulmonary large cell neuroendocrine carcinoma (LCNEC) and ~35% of extra‐thoracic LCNEC patients [9].